Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-28
DOI
10.1186/s12933-022-01489-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials
- (2021) Apostolos Tsapas et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Comparison of propensity score methods for pre-specified subgroup analysis with survival data
- (2020) Rima Izem et al. Journal of Biopharmaceutical Statistics
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
- (2020) Matthew J. Crowley et al. DIABETES CARE
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
- (2020) Mansoor Husain et al. Cardiovascular Diabetology
- Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58
- (2020) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
- (2020) Francesco Zaccardi et al. DIABETES CARE
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
- (2020) Giulia Ferrannini et al. EUROPEAN HEART JOURNAL
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- (2019) Silvio E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing
- (2017) Lisa Schlender et al. BMC Geriatrics
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started